Armata Pharmaceuticals, Inc.

AMEX:ARMP

Biotechnology

Healthcare
$3.17 -0.28%

-$0.02 today

Market cap
$117.90M
Beta
1.22
P/E (TTM)
-0.9
EPS (TTM)
-$7.74
52W Low $1.81High $16.34

Volume 0.09M

Average 0.07M

ARMP Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Armata Pharmaceuticals, Inc.AMEX: ARMP

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin narrows to -14619.3%

Net margin was -14619.3% in Q1 FY2026, down 13289.1 pp from a year earlier. On a trailing-twelve-month basis it was -9554.2%, down 9545.2 pp year over year. Over 3 fiscal years it narrowed by 2873.8 pp.

Context

  • Net margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 1 analysts of -471.4% for the fiscal year ending Dec 2026, up from -3544.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-14619.3%— QoQ
Last fiscal yearDec 2025
-3544.0%-3178.4 pp YoY
LTMMar 2026
-9554.2%-9545.2 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-13289.1 pp-6221.8 pp+7067.3 pp
1 year-3178.4 pp+3072.6 pp+6251.0 pp
3 years-2873.8 pp+3473.9 pp+6347.6 pp
5 years+3532.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-3544.0%
Year-over-year change
-3178.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How ARMP compares with its peers on the latest reported figures

  • ARMP's LTM Mar 2026 net margin of -9554.2% is the lowest of the 2 companies compared; the peer median is 27.8%.
  • Its year-over-year change of -9545.2 pp is the lowest of 2, against a peer median of +184.3 pp.
  • Over three fiscal years its change of -2873.8 pp compares with a peer median of +109.9 pp.
ARMP Competitors Peer median
Net Margin for ARMP and competitors
Company Period LTM level YoY 3-year change
SPROSpero Therapeutics, Inc.LTM Mar 202627.8% +184.3 pp+109.9 pp
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026-9554.2% -9545.2 pp-2873.8 pp
Peer median (excluding ARMP) 27.8%+184.3 pp+109.9 pp

Competitors are the stored peer set for ARMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.47M5.51M4.53M5.17M4.9M
Cost of Revenue20.02M35.02M972K34.43M1.53M
Gross Profit(15.54M)(29.51M)3.56M(29.25M)3.37M
Gross Margin-347.4%-535.7%78.5%-565.4%68.8%
Research & Development20.02M35.02M33.77M34.43M23.72M
Selling, General & Admin8.28M7.44M10.68M13.18M12.41M
Operating Expenses8.28M7.44M44.45M13.18M34.6M
Depreciation & Amortization1.17M892K972K1.33M1.53M
EBITDA(21.92M)(36M)(65.45M)(6.85M)(155.68M)
EBITDA Margin-490.0%-653.5%-1445.1%-132.4%-3174.5%
Operating Income(23.82M)(36.95M)(40.89M)(42.44M)(31.22M)
Operating Margin-532.5%-670.8%-902.8%-820.2%-636.7%
Interest Income5K29K179K697K388K
Interest Expense64K29K2.63M10.74M16.59M
Other Income / Expenses667K29K(28.16M)23.52M(142.58M)
Income Before Tax(23.16M)(36.92M)(69.05M)(18.92M)(173.8M)
Pre-Tax Margin-517.5%-670.2%-1524.5%-365.6%-3544.0%
Income Tax Expense00000
Net Income(23.16M)(36.92M)(69.05M)(18.92M)(173.8M)
Net Margin-517.5%-670.2%-1524.5%-365.6%-3544.0%
EPS (Basic)(0.96)(1.08)(1.91)(0.52)(4.80)
EPS (Diluted)(0.96)(1.08)(1.91)(0.52)(4.80)
Weighted Avg Shares24.1M34.29M36.08M36.16M36.24M
Weighted Avg Shares (Diluted)24.1M34.29M36.08M36.16M36.24M

Armata Pharmaceuticals, Inc.

AMEX:ARMP

Intrinsic Alpha fair value

Locked

Current Price

$3.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.